

AVENTIS BEHRING GMBH

2002/M014J (A54)

Claims:

- 5 1. A pharmaceutical preparation which comprises an amount, sufficient for promoting coagulation, of natural or synthetic RNA or of one or more coagulation-promoting fragments of natural or synthetic RNA, RNA analogs such as peptide-nucleic acids, ribozymes or RNA aptamers.
- 10 2. A pharmaceutical preparation as claimed in claim 1, which, in addition to the amount promoting coagulation, of natural or synthetic RNA or of one or more coagulation-promoting fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers, comprises an activator for a plasma coagulation factor.
- 15 3. A pharmaceutical preparation as claimed in claim 2, which comprises factor VII activating protease (=FSAP) or its proenzyme as activator.
- 20 4. The use of a pharmaceutical preparation as claimed in claims 1 to 3, which is employed for promoting coagulation.
5. A pharmaceutical preparation, which comprises an amount, sufficient for promoting fibrinolysis or inhibiting coagulation, of one or more
25 RNA-degrading or -inhibiting compounds with ribonucleolytic activity or RNA-complexing capacity.
6. A pharmaceutical preparation as claimed in claim 5, which, in addition to an amount, sufficient for promoting fibrinolysis or inhibiting
30 coagulation, of one or more RNA-degrading, -inhibiting or -masking compounds, comprises an activator for a plasma fibrinolytic.
7. A pharmaceutical preparation as claimed in claim 6, which comprises a plasminogen activator-activating protease FSAP or its
35 proenzyme as activator for a plasma fibrinolytic.
8. A diagnostic aid for detecting inter alia postoperative hypercoagulable states, complications of pregnancy, tumor status, acute myocardial infarction or sepsis, which comprises detection of an increased

plasma RNA content compared with healthy people.

9. A diagnostic aid for quantitative or qualitative detection of coagulation factor VII-activating protease FSAP or of its proenzyme, which
5 comprises, for determination

- a) of the inactivating effect on coagulation factors VIII/VIIIa or V/Va or
- 10 b) of the shortening effect on coagulation times in global coagulation tests or
- c) of the activating effect on plasminogen activators or
- d) of the activating effect on FVII

15

a sufficient amount of natural or synthetic RNA, of active fragments of natural or synthetic RNA or RNA analogs such as peptide-nucleic acids, ribozymes or RNA aptamers.

20 10. A diagnostic aid as claimed in claim 8, which comprises, for determination of the effect shortening the coagulation time by means

- a) of the non-activated partial thromboplastin time (NAPTT) or
- 25 b) of the prothrombin time (PT) or
- c) of the plasma recalcification time or
- d) of the activated partial thromboplastin time (APTT)

30

a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers.

11. A diagnostic aid as claimed in claims 8 and 9, which comprises, for
35 determination of the effect activating or enhancing the plasminogen activators through the activation

- a) of single-chain urokinase (scuPA, single-chain urokinase plasminogen activator) or

b) of single-chain tPA (sctPA, single-chain tissue plasminogen activator),

5 a sufficient amount of natural or synthetic RNA, active fragments of natural or synthetic RNA, peptide-nucleic acids, ribozymes or RNA aptamers.

12. A pharmaceutical preparation as claimed in claim 5, which comprises an amount, sufficient for the treatment of sepsis, of one or more RNA-degrading, inhibiting or complexing compounds.